1. Home
  2. IDYA vs ADX Comparison

IDYA vs ADX Comparison

Compare IDYA & ADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IDYA
  • ADX
  • Stock Information
  • Founded
  • IDYA 2015
  • ADX 1840
  • Country
  • IDYA United States
  • ADX United States
  • Employees
  • IDYA N/A
  • ADX N/A
  • Industry
  • IDYA Biotechnology: Pharmaceutical Preparations
  • ADX Investment Managers
  • Sector
  • IDYA Health Care
  • ADX Finance
  • Exchange
  • IDYA Nasdaq
  • ADX Nasdaq
  • Market Cap
  • IDYA 2.9B
  • ADX 2.7B
  • IPO Year
  • IDYA 2019
  • ADX N/A
  • Fundamental
  • Price
  • IDYA $34.21
  • ADX $22.85
  • Analyst Decision
  • IDYA Buy
  • ADX
  • Analyst Count
  • IDYA 14
  • ADX 0
  • Target Price
  • IDYA $49.58
  • ADX N/A
  • AVG Volume (30 Days)
  • IDYA 992.0K
  • ADX 182.4K
  • Earning Date
  • IDYA 11-04-2025
  • ADX 01-01-0001
  • Dividend Yield
  • IDYA N/A
  • ADX 6.68%
  • EPS Growth
  • IDYA N/A
  • ADX N/A
  • EPS
  • IDYA N/A
  • ADX N/A
  • Revenue
  • IDYA $214,834,000.00
  • ADX N/A
  • Revenue This Year
  • IDYA $90.17
  • ADX N/A
  • Revenue Next Year
  • IDYA $217.29
  • ADX N/A
  • P/E Ratio
  • IDYA N/A
  • ADX N/A
  • Revenue Growth
  • IDYA 5377.66
  • ADX N/A
  • 52 Week Low
  • IDYA $13.45
  • ADX $14.94
  • 52 Week High
  • IDYA $34.66
  • ADX $19.57
  • Technical
  • Relative Strength Index (RSI)
  • IDYA 68.23
  • ADX 47.01
  • Support Level
  • IDYA $31.15
  • ADX $22.95
  • Resistance Level
  • IDYA $34.66
  • ADX $23.85
  • Average True Range (ATR)
  • IDYA 1.58
  • ADX 0.35
  • MACD
  • IDYA 0.11
  • ADX -0.05
  • Stochastic Oscillator
  • IDYA 89.86
  • ADX 20.90

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About ADX Adams Diversified Equity Fund Inc.

Adams Diversified Equity Fund Inc is a diversified investment company. It is an internally managed closed-end fund whose investment objectives are the preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation. It invests a majority of its assets in very liquid S&P 500 stocks, and has broad flexibility in the selection of stocks, but maintains a sector neutral approach. The fund has a diversified equity portfolio which consists of securities of companies from energy, consumer staples, information technology, financials, and other sectors.

Share on Social Networks: